BrainStorm Cell Therapeutics Announces Upcoming Investor Call
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a prominent player in developing adult stem cell therapies for neurodegenerative diseases, is set to hold an important investor call. This call is scheduled for December 30, 2024, at 8:30 AM Eastern Time. The details of the call were shared recently, emphasizing its significance for stakeholders considering the company’s advancements in treatment options.
Key Updates from Company Leadership
During the call, BrainStorm's President and CEO, Chaim Lebovits, will take the lead in presenting the latest developments within the company. Additionally, key figures such as Hartoun Hartounian, PhD, the Chief Operating Officer and EVP, and Bob Dagher, MD, the Chief Development Officer, will also participate, lending their expertise to the discussion.
The leadership team aims to provide valuable insights into ongoing projects and addressing future strategies. This interactive session will not only include prepared remarks but also a Q&A segment, where participants can engage with company executives directly.
How to Participate in the Investor Conference Call
Attendees who wish to take part in the investor call can do so by dialing the U.S. number 888-506-0062 or the international line at 973-528-0011. For those interested, the participant access code is 225269. This is a unique opportunity for investors to hear directly from the team driving innovative treatments for debilitating conditions.
To accommodate those unable to attend the live session, a replay of the call will be accessible, ensuring that all stakeholders can stay informed. Details for the replay will be made available during the call.
Upcoming Key Opinion Leader Webinar
In addition to the investor call, BrainStorm is scheduled to host a Key Opinion Leader (KOL) Webinar centered on the “Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS)” on December 11, 2024, at 10:00 AM Eastern Time. This webinar will showcase a presentation by Dr. Terry Heiman Patterson, a distinguished figure in neurology, who will discuss significant advancements in ALS treatments.
Participation in this webinar will provide deeper insights into the ongoing research and developments within the field of neurodegenerative disorders, highlighting BrainStorm’s commitment to pioneering effective therapies.
About BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc. is dedicated to transforming the treatment landscape for neurodegenerative diseases. The company is making strides with its NurOwn® technology platform, focusing on developing autologous MSC-NTF cells. These innovative therapies have received orphan drug designation from regulatory bodies and demonstrate BrainStorm's commitment to addressing critical medical needs.
The company is currently preparing for a Phase 3b trial in ALS to evaluate the safety and effectiveness of its therapeutic approaches further. In addition to its stem cell therapies, BrainStorm is leveraging exosome technology, which allows for targeted delivery of bioactive molecules, presenting a new horizon in treating diseases affecting the nervous system.
Through sustained research efforts and clinical trials, including those supported by reputable organizations, BrainStorm remains at the forefront of developing solutions that can significantly improve patient outcomes in neurodegenerative diseases.
Frequently Asked Questions
What is the purpose of the investor call?
The investor call is intended to provide updates on the company’s progress and future strategies, allowing stakeholders to engage directly with the leadership team.
Who will be speaking during the call?
Chaim Lebovits, Hartoun Hartounian, and Bob Dagher are key speakers for the upcoming investor call.
How can I submit questions for the Q&A session?
Participants are encouraged to submit their questions in advance by contacting the company at the email provided prior to the call.
What is the significance of the KOL Webinar?
The KOL Webinar will provide insights into the latest advancements in the treatment of ALS, featuring recognized experts in the field.
What is NurOwn and its relevance to BrainStorm?
NurOwn is BrainStorm's innovative therapy platform designed to treat neurodegenerative conditions, and it is crucial for the company’s development in ALS research.
